Education
About Us
Working with TipRanks
Follow Us
Bausch Health Companies (TSE:BHC)
TSX:BHC
BHC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$5.91 - C$13.74
Previous CloseN/A
Volume45.48K
Average Volume (3M)438.45K
Market Cap
$4.26B
Enterprise ValueC$31.91B
Total Cash (Recent Filing)$1.73B
Total Debt (Recent Filing)$21.74B
Price to Earnings (P/E)31.8
Beta1.29
Next Earnings
Oct 30, 2025EPS Estimate
1.53Last Dividend Ex-Date
Aug 30, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)1.45
Shares Outstanding369,790,300
10 Day Avg. Volume724,483
30 Day Avg. Volume438,455
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap7.49
Enterprise Value/Revenue3.24
Enterprise Value/Gross Profit4.58
Enterprise Value/Ebitda10.64
Forecast
1Y Price Target
$11.75Price Target Upside1.98% Upside
Rating ConsensusHold
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Revenue PerformanceBHC total revenue in Q2 of $2,530MM was $35MM above the estimate.
Sales SuccessSalix Segment sales beat the forecast by $37MM, supported by a successful DTC campaign for Xifaxan.
Shareholder ValueBausch Health Companies introduced the option of a share buyback as part of its capital allocation strategy, indicating a focus on returning value to shareholders.
Bears Say
Debt And Interest ExpensesInterest expense was significantly higher than estimated due to refinancing debt at less favorable rates.
Operating And Earnings PerformanceOperating income and EPS were below expectations due to higher SG&A spending and increased interest expenses.
Spin-off UncertaintyAnalyst reiterates an underperform rating due to uncertainty around execution of Bausch's eye health subsidiary divestiture and cautious outlook on Pharma business post-Xifaxan loss of exclusivity.
Bausch Health Companies News
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was C$5.91 and its highest was C$13.74 in the past 12 months.
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is $4.26B.
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Oct 30, 2025 which is in 73 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Jul 30, 2025. The company reported C$1.447 earnings per share for the quarter, beating the consensus estimate of C$1.272 by C$0.175.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of C$0.097 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is 1.53.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 369,790,300 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of C$1.447 in its last earnings report, beating expectations of C$1.272. Following the earnings report the stock price went down -7.684%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Currently, no hedge funds are holding shares in TSE:BHC
Bausch Health Companies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$11.75 (1.98% Upside)
$11.75 (1.98% Upside)
Blogger Sentiment
Bullish
TSE:BHC Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $369.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.29%
12-Months-Change
Fundamentals
Return on Equity
3.60%
Trailing 12-Months
Asset Growth
2.91%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
BHC Company Deck
BHC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong overall performance with consistent growth in key segments and strategic initiatives like the acquisition of DURECT Corporation. However, challenges such as revenue declines in the diversified segment and potential impacts from IRA negotiations were noted. Despite these issues, the company's positive growth trajectory and strategic actions suggest a favorable outlook.View all TSE:BHC earnings summariesBHC Revenue Breakdown
47.34% Bausch + Lomb
25.69% Salix
12.23% International
10.77% Diversified Products
3.96% Solta Medical
BHC Stock 12 Month Forecast
Average Price Target
C$11.75
▲(1.98% Upside)
Technical Analysis
Theratechnologies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Cronos Group
―
HLS Therapeutics Inc
―
Ownership Overview
20.26% Insiders
3.84%
Mutual Funds
0.07% Other Institutional Investors
71.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---